Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 21, Issue 42, 2015, Pages 12022-12041

  Varshosaz, Jaleh ^a   Farzan, Maryam ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Chemotherapeutic agents; Hepatocellular carcinoma; Nanoparticle; Small interfering RNA; Targeted delivery

Indexed keywords

ANTIESTROGEN; ARGINYLGLYCYLASPARTIC ACID; ASIALOGLYCOPROTEIN RECEPTOR; BEVACIZUMAB; CELL SURFACE RECEPTOR; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FOLATE RECEPTOR; GANGLIOSIDE GM1; GEMCITABINE; INTEGRIN RECEPTOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MONOCLONAL ANTIBODY; NANOCARRIER; OCTREOTIDE; OXALIPLATIN; RETINOIC ACID RECEPTOR; SMALL INTERFERING RNA; SORAFENIB; TAMOXIFEN; TRANSFERRIN RECEPTOR; ANTINEOPLASTIC AGENT; DRUG CARRIER; NANOPARTICLE;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CHEMOEMBOLIZATION; CLINICAL FEATURE; DRUG TARGETING; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; INTERVENTIONAL RADIOLOGY; LIVER CELL CARCINOMA; META ANALYSIS (TOPIC); NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANIMAL; BIOAVAILABILITY; CARCINOMA, HEPATOCELLULAR; CHEMISTRY; GENE TRANSFER; GENETICS; LIVER NEOPLASMS; MEDICINAL CHEMISTRY; METABOLISM; MOLECULARLY TARGETED THERAPY; NANOMEDICINE; PATHOLOGY; PROCEDURES; RNA STABILITY; RNAI THERAPEUTICS;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CARCINOMA, HEPATOCELLULAR; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; GENE TRANSFER TECHNIQUES; HUMANS; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; NANOMEDICINE; NANOPARTICLES; RNA STABILITY; RNA, SMALL INTERFERING; RNAI THERAPEUTICS;

EID: 84947436450     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i42.12022     Document Type: Article

References (142)

1. Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol 2008; 14: 4300-4308 [PMID: 18666317 DOI: 10.3748/wjg.14.4300]
2. Bosch FX, Ribes J, Cléries R, Díaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005; 9: 191-211, v [PMID: 15831268 DOI: 10.1016/j.cld.2004.12.009]
3. Altekruse SF, Henley SJ, Cucinelli JE, McGlynn KA. Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol 2014; 109: 542-553 [PMID: 24513805 DOI: 10.1038/ajg.2014.11]
4. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576 [PMID: 17570226 DOI: 10.1053/j.gastro.2007.04.061]
5. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35: 519-524 [PMID: 11870363 DOI: 10.1053/jhep.2002.32089]
6. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917 [PMID: 14667750 DOI: 10.1016/S0140-6736(03)14964-1]
7. Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002; 122: 1609-1619 [PMID: 12016426 DOI: 10.1053/gast.2002.33411]
8. Trevisani F, De Notariis S, Rapaccini G, Farinati F, Benvegnù L, Zoli M, Grazi GL, Del PP, Di N, Bernardi M. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 2002; 97: 734-744 [PMID: 11922571 DOI: 10.1111/j.1572-0241.2002.05557.x]
9. Zhang B, Yang B. Combined alpha fetoprotein testing and ultrasonography as a screening test for primary liver cancer. J Med Screen 1999; 6: 108-110 [PMID: 10444731 DOI: 10.1016/S0895-4356(98)90045-2]
10. Bruix J, Hessheimer AJ, Forner A, Boix L, Vilana R, Llovet JM. New aspects of diagnosis and therapy of hepatocellular carcinoma. Oncogene 2006; 25: 3848-3856 [PMID: 16799626 DOI: 10.1038/sj.onc.1209548]
11. Forner A, Hessheimer AJ, Isabel Real M, Bruix J. Treatment of hepatocellular carcinoma. Crit Rev Oncol Hematol 2006; 60: 89-98 [PMID: 16860993 DOI: 10.1016/j.critrevonc.2006.06.001]
12. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236 [PMID: 16250051 DOI: 10.1002/hep.20933]
13. Chlebowski RT, Brzechwa-Adjukiewicz A, Cowden A, Block JB, Tong M, Chan KK. Doxorubicin (75 mg/m2) for hepatocellular carcinoma: clinical and pharmacokinetic results. Cancer Treat Rep 1984; 68: 487-491 [PMID: 6322986]
14. Nerenstone SR, Ihde DC, Friedman MA. Clinical trials in primary hepatocellular carcinoma: current status and future directions. Cancer Treat Rev 1988; 15: 1-31 [PMID: 2834053 DOI: 10.1016/0 305-7372(88)90007-2]
15. Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, Koh J, Mo FK, Yu SC, Chan AT, Hui P, Ma B, Lam KC, Ho WM, Wong HT, Tang A, Johnson PJ. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005; 97: 1532-1538 [PMID: 16234567 DOI: 10.1093/jnci/dji315]
16. Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K, Sheehan S, Hale KE, Enzinger PC, Bhargava P, Stuart K. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 1898-1903 [PMID: 16622265 DOI: 10.1200/JCO.2005.04.9130]
17. Kim RD, Reed AI, Fujita S, Foley DP, Mekeel KL, Hemming AW. Consensus and controversy in the management of hepatocellular carcinoma. J Am Coll Surg 2007; 205: 108-123 [PMID: 17617340 DOI: 10.1016/j.jamcollsurg.2007.02.025]
18. Chang YS, Adnane J, Trail PA, Levy J, Henderson A, Xue D, Bortolon E, Ichetovkin M, Chen C, McNabola A, Wilkie D, Carter CA, Taylor IC, Lynch M, Wilhelm S. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 2007; 59: 561-574 [PMID: 17160391 DOI: 10.1007/s00280-006-0393-4]
19. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109 [PMID: 15466206 DOI: 10.1158/0008-5472.CAN-04-1443]
20. Zhang T, Ding X, Wei D, Cheng P, Su X, Liu H, Wang D, Gao H. Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials. Anticancer Drugs 2010; 21: 326-332 [PMID: 20016366 DOI: 10.1097/CAD.0b013e3283350e26]
21. Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, Chen H, Clark-Garvey S, Weinberg A, Mandeli J, Christos P, Mazumdar M, Popa E, Brown RS, Rafii S, Schwartz JD. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008; 26: 2992-2998 [PMID: 18565886 DOI: 10.1200/JCO.2007.15.9947]
22. Huether A, Höpfner M, Sutter AP, Schuppan D, Scherübl H. Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics. J Hepatol 2005; 43: 661-669 [PMID: 16023762 DOI: 10.1016/j.jhep.2005.02.040]
23. Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009; 27: 3027-3035 [PMID: 19470923 DOI: 10.1200/JCO.2008.20.9908]
24. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008; 48 Suppl 1: S20-S37 [PMID: 18304676 DOI: 10.1016/j.jhep.2008.01.022]
25. Devi GR. siRNA-based approaches in cancer therapy. Cancer Gene Ther 2006; 13: 819-829 [PMID: 16424918 DOI: 10.1038/sj.cgt.7700931]
26. Lee YH, Judge AD, Seo D, Kitade M, Gómez-Quiroz LE, Ishikawa T, Andersen JB, Kim BK, Marquardt JU, Raggi C, Avital I, Conner EA, MacLachlan I, Factor VM, Thorgeirsson SS. Molecular targeting of CSN5 in human hepatocellular carcinoma: a mechanism of therapeutic response. Oncogene 2011; 30: 4175-4184 [PMID: 21499307 DOI: 10.1038/onc.2011.126]
27. Li K, Lin SY, Brunicardi FC, Seu P. Use of RNA interference to target cyclin E-overexpressing hepatocellular carcinoma. Cancer Res 2003; 63: 3593-3597 [PMID: 12839946]
28. Raskopf E, Vogt A, Sauerbruch T, Schmitz V. siRNA targeting VEGF inhibits hepatocellular carcinoma growth and tumor angiogenesis in vivo. J Hepatol 2008; 49: 977-984 [PMID: 18845354 DOI: 10.1016/j.jhep.2008.07.022]
29. Zhao Y, Jian W, Gao W, Zheng YX, Wang YK, Zhou ZQ, Zhang H, Wang CJ. RNAi silencing of c-Myc inhibits cell migration, invasion, and proliferation in HepG2 human hepatocellular carcinoma cell line: c-Myc silencing in hepatocellular carcinoma cell. Cancer Cell Int 2013; 13: 23 [PMID: 23497309 DOI: 10.1186/1475-2867-13-23]
30. Scaggiante B, Kazemi M, Pozzato G, Dapas B, Farra R, Grassi M, Zanconati F, Grassi G. Novel hepatocellular carcinoma molecules with prognostic and therapeutic potentials. World J Gastroenterol 2014; 20: 1268-1288 [PMID: 24574801 DOI: 10.3748/wjg.v20. i5.1268]
31. Li L, Wang R, Wilcox D, Sarthy A, Lin X, Huang X, Tian L, Dande P, Hubbard RD, Hansen TM, Wada C, Zhao X, Kohlbrenner WM, Fesik SW, Shen Y. Developing lipid nanoparticle-based siRNA therapeutics for hepatocellular carcinoma using an integrated approach. Mol Cancer Ther 2013; 12: 2308-2318 [PMID: 23943805 DOI: 10.1158/1535-7163.MCT-12-0983-T]
32. Doan CC, Doan NT, Nguyen QH, Nguyen MH, Do MS, Le VD. Downregulation of Kinesin spindle protein inhibits proliferation, induces apoptosis and increases chemosensitivity in hepatocellular carcinoma cells. Iran Biomed J 2015; 19: 1-16 [PMID: 25605484]
33. Zhang L, He T, Cui H, Wang Y, Huang C, Han F. Effects of AFP gene silencing on apoptosis and proliferation of a hepatocellular carcinoma cell line. Discov Med 2012; 14: 115-124 [PMID: 22935208]
34. Li H, Fu X, Chen Y, Hong Y, Tan Y, Cao H, Wu M, Wang H. Use of adenovirus-delivered siRNA to target oncoprotein p28GANK in hepatocellular carcinoma. Gastroenterology 2005; 128: 2029-2041 [PMID: 15940635]
35. Steichen SD, Caldorera-Moore M, Peppas NA. A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur J Pharm Sci 2013; 48: 416-427 [PMID: 23262059 DOI: 10.1016/j.ejps.2012.12.006]
36. Soll C, Riener MO, Oberkofler CE, Hellerbrand C, Wild PJ, DeOliveira ML, Clavien PA. Expression of serotonin receptors in human hepatocellular cancer. Clin Cancer Res 2012; 18: 5902-5910 [PMID: 23087410 DOI: 10.1158/1078-0432.CCR-11-1813]
37. Li YH, Liu Y, Li YD, Liu YH, Li F, Ju Q, Xie PL, Li GC. GABA stimulates human hepatocellular carcinoma growth through overexpressed GABAA receptor theta subunit. World J Gastroenterol 2012; 18: 2704-2711 [PMID: 22690081 DOI: 10.3748/wjg.v18. i21.2704]
38. Qiu WH, Zhou BS, Chu PG, Chen WG, Chung C, Shih J, Hwu P, Yeh C, Lopez R, Yen Y. Over-expression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma. World J Gastroenterol 2005; 11: 5266-5272 [PMID: 16149130]
39. Buckley AF, Burgart LJ, Sahai V, Kakar S. Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma. Am J Clin Pathol 2008; 129: 245-251 [PMID: 18208805 DOI: 10.1309/WF10QAAED3PP93BH]
40. Abdel-Rahman O, Lamarca A, Valle JW, Hubner RA. Somatostatin receptor expression in hepatocellular carcinoma: prognostic and therapeutic considerations. Endocr Relat Cancer 2014; 21: R485-R493 [PMID: 25336571 DOI: 10.1530/ERC-14-0389]
41. Chettouh H, Fartoux L, Aoudjehane L, Wendum D, Clapéron A, Chrétien Y, Rey C, Scatton O, Soubrane O, Conti F, Praz F, Housset C, Rosmorduc O, Desbois-Mouthon C. Mitogenic insulin receptor-A is overexpressed in human hepatocellular carcinoma due to EGFR-mediated dysregulation of RNA splicing factors. Cancer Res 2013; 73: 3974-3986 [PMID: 23633480 DOI: 10.1158/0008-5472.CAN-12-3824]
42. Bai X, Wang J, Guo Y, Pan J, Yang Q, Zhang M, Li H, Zhang L, Ma J, Shi F, Shu W, Wang Y, Leng J. Prostaglandin E2 stimulates β1-integrin expression in hepatocellular carcinoma through the EP1 receptor/PKC/NF-κB pathway. Sci Rep 2014; 4: 6538 [PMID: 25289898 DOI: 10.1038/srep06538]
43. Xiang HJ, Liu ZC, Wang DS, Chen Y, Yang YL, Dou KF. Adenosine A(2b) receptor is highly expressed in human hepatocellular carcinoma. Hepatol Res 2006; 36: 56-60 [PMID: 16844405 DOI: 10.1016/j.hepres.2006.06.008]
44. Chun YS, Huang M, Rink L, Von Mehren M. Expression levels of insulin-like growth factors and receptors in hepatocellular carcinoma: a retrospective study. World J Surg Oncol 2014; 12: 231. [PMID: 25052889 DOI: 10.1186/1477-7819-12-231]
45. Shi B, Abrams M, Sepp-Lorenzino L. Expression of asialoglycoprotein receptor 1 in human hepatocellular carcinoma. J Histochem Cytochem 2013; 61: 901-909 [PMID: 23979840 DOI: 10.1369/0022155413503662]
46. Ma WL, Lai HC, Yeh S, Cai X, Chang C. Androgen receptor roles in hepatocellular carcinoma, fatty liver, cirrhosis and hepatitis. Endocr Relat Cancer 2014; 21: R165-R182 [PMID: 24424503 DOI: 10.1530/ERC-13-0283]
47. Kelemen LE. The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander? Int J Cancer 2006; 119: 243-250 [PMID: 16453285 DOI: 10.1002/ijc.21712]
48. Högemann-Savellano D, Bos E, Blondet C, Sato F, Abe T, Josephson L, Weissleder R, Gaudet J, Sgroi D, Peters PJ, Basilion JP. The transferrin receptor: a potential molecular imaging marker for human cancer. Neoplasia 2003; 5: 495-506 [PMID: 14965443]
49. Niitsu Y, Kohgo Y, Nishisato T, Kondo H, Kato J, Urushizaki Y, Urushizaki I. Transferrin receptors in human cancerous tissues. Tohoku J Exp Med 1987; 153: 239-243 [PMID: 3433281]
50. Nakamaki T, Kawabata H, Saito B, Matsunawa M, Suzuki J, Adachi D, Tomoyasu S, Phillip Koeffler H. Elevated levels of transferrin receptor 2 mRNA, not transferrin receptor 1 mRNA, are associated with increased survival in acute myeloid leukaemia. Br J Haematol 2004; 125: 42-49 [PMID: 15015967]
51. Yan JJ, Liao JZ, Lin JS, He XX. Active radar guides missile to its target: receptor-based targeted treatment of hepatocellular carcinoma by nanoparticulate systems. Tumour Biol 2015; 36: 55-67 [PMID: 25424700 DOI: 10.1007/s13277-014-2855-3]
52. Sano K, Takayama T, Murakami K, Saiki I, Makuuchi M. Overexpression of retinoic acid receptor alpha in hepatocellular carcinoma. Clin Cancer Res 2003; 9: 3679-3683 [PMID: 14506158]
53. Lenter MC, Garidel P, Pelisek J, Wagner E, Ogris M. Stabilized nonviral formulations for the delivery of MCP-1 gene into cells of the vasculoendothelial system. Pharm Res 2004; 21: 683-691 [PMID: 15139526]
54. Mishra S, Webster P, Davis ME. PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. Eur J Cell Biol 2004; 83: 97-111 [PMID: 15202568 DOI: 10.1078/0171-9335-00363]
55. Ogris M, Walker G, Blessing T, Kircheis R, Wolschek M, Wagner E. Tumor-targeted gene therapy: strategies for the preparation of ligand-polyethylene glycol-polyethylenimine/DNA complexes. J Control Release 2003; 91: 173-181 [PMID: 12932649]
56. Pun SH, Tack F, Bellocq NC, Cheng J, Grubbs BH, Jensen GS, Davis ME, Brewster M, Janicot M, Janssens B, Floren W, Bakker A. Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles. Cancer Biol Ther 2004; 3: 641-650 [PMID: 15136766]
57. Sanders NN, De Smedt SC, Cheng SH, Demeester J. Pegylated GL67 lipoplexes retain their gene transfection activity after exposure to components of CF mucus. Gene Ther 2002; 9: 363-371 [PMID: 11960312 DOI: 10.1038/sj.gt.3301663]
58. Suh J, Wirtz D, Hanes J. Real-time intracellular transport of gene nanocarriers studied by multiple particle tracking. Biotechnol Prog 2004; 20: 598-602 [PMID: 15059007 DOI: 10.1021/bp034251y]
59. Zahr AS, de Villiers M, Pishko MV. Encapsulation of drug nanoparticles in self-assembled macromolecular nanoshells. Langmuir 2005; 21: 403-410 [PMID: 15620331 DOI: 10.1021/la0478595]
60. Lai SK, O'Hanlon DE, Harrold S, Man ST, Wang YY, Cone R, Hanes J. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc Natl Acad Sci USA 2007; 104: 1482-1487 [PMID: 17244708 DOI: 10.1073/pnas.0608611104]
61. Suh J, Choy KL, Lai SK, Suk JS, Tang BC, Prabhu S, Hanes J. PEGylation of nanoparticles improves their cytoplasmic transport. Int J Nanomedicine 2007; 2: 735-741 [PMID: 18203439]
62. Xu M, Qian J, Suo A, Wang H, Yong X, Liu X, Liu R. Reduction/pH dual-sensitive PEGylated hyaluronan nanoparticles for targeted doxorubicin delivery. Carbohydr Polym 2013; 98: 181-188 [PMID: 23987334 DOI: 10.1016/j.carbpol.2013.05.077]
63. Liu Q, Li R, Zhu Z, Qian X, Guan W, Yu L, Yang M, Jiang X, Liu B. Enhanced antitumor efficacy, biodistribution and penetration of docetaxel-loaded biodegradable nanoparticles. Int J Pharm 2012; 430: 350-358 [PMID: 22525076 DOI: 10.1016/j.ijpharm.2012.04.008]
64. Ashley CE, Carnes EC, Phillips GK, Padilla D, Durfee PN, Brown PA, Hanna TN, Liu J, Phillips B, Carter MB, Carroll NJ, Jiang X, Dunphy DR, Willman CL, Petsev DN, Evans DG, Parikh AN, Chackerian B, Wharton W, Peabody DS, Brinker CJ. The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. Nat Mater 2011; 10: 389-397 [PMID: 21499315 DOI: 10.1038/nmat2992]
65. Muñoz-Gámez JA, López Viota J, Barrientos A, Carazo Á, Sanjuán-Nuñez L, Quiles-Perez R, Muñoz-de-Rueda P, Delgado Á, Ruiz-Extremera Á, Salmerón J. Synergistic cytotoxicity of the poly (ADP-ribose) polymerase inhibitor ABT-888 and temozolomide in dual-drug targeted magnetic nanoparticles. Liver Int 2015; 35: 1430-1441 [PMID: 24821649 DOI: 10.1111/liv.12586]
66. Cheng M, Gao X, Wang Y, Chen H, He B, Xu H, Li Y, Han J, Zhang Z. Synthesis of glycyrrhetinic acid-modified chitosan 5-fluorouracil nanoparticles and its inhibition of liver cancer characteristics in vitro and in vivo. Mar Drugs 2013; 11: 3517-3536 [PMID: 24048270 DOI: 10.3390/md11093517]
67. Zu Y, Meng L, Zhao X, Ge Y, Yu X, Zhang Y, Deng Y. Preparation of 10-hydroxycamptothecin-loaded glycyrrhizic acid-conjugated bovine serum albumin nanoparticles for hepatocellular carcinomatargeted drug delivery. Int J Nanomedicine 2013; 8: 1207-1222 [PMID: 23569373 DOI: 10.2147/IJN.S40493]
68. Shi L, Tang C, Yin C. Glycyrrhizin-modified O-carboxymethyl chitosan nanoparticles as drug vehicles targeting hepatocellular carcinoma. Biomaterials 2012; 33: 7594-7604 [PMID: 22796165 DOI: 10.1016/j.biomaterials.2012.06.072]
69. Zhang L, Yao J, Zhou J, Wang T, Zhang Q. Glycyrrhetinic acidgraft-hyaluronic acid conjugate as a carrier for synergistic targeted delivery of antitumor drugs. Int J Pharm 2013; 441: 654-664 [PMID: 23117024 DOI: 10.1016/j.ijpharm.2012.10.030]
70. Guo H, Lai Q, Wang W, Wu Y, Zhang C, Liu Y, Yuan Z. Functional alginate nanoparticles for efficient intracellular release of doxorubicin and hepatoma carcinoma cell targeting therapy. Int J Pharm 2013; 451: 1-11 [PMID: 23618965 DOI: 10.1016/j.ijpharm.2013.04.025]
71. Varshosaz J, Hassanzadeh F, Sadeghi H, Khadem M. Galactosylated nanostructured lipid carriers for delivery of 5-FU to hepatocellular carcinoma. J Liposome Res 2012; 22: 224-236 [PMID: 22385296 DOI: 10.3109/08982104.2012.662653]
72. Zhou N, Zan X, Wang Z, Wu H, Yin D, Liao C, Wan Y. Galactosylated chitosan-polycaprolactone nanoparticles for hepatocyte-targeted delivery of curcumin. Carbohydr Polym 2013; 94: 420-429 [PMID: 23544558 DOI: 10.1016/j.carbpol.2013.01.014]
73. Zhou X, Zhang M, Yung B, Li H, Zhou C, Lee LJ, Lee RJ. Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma. Int J Nanomedicine 2012; 7: 5465-5474 [PMID: 23093902 DOI: 10.2147/IJN.S33965]
74. Cheng M, He B, Wan T, Zhu W, Han J, Zha B, Chen H, Yang F, Li Q, Wang W, Xu H, Ye T. 5-Fluorouracil nanoparticles inhibit hepatocellular carcinoma via activation of the p53 pathway in the orthotopic transplant mouse model. PLoS One 2012; 7: e47115 [PMID: 23077553 DOI: 10.1371/journal.pone.0047115]
75. Cheng MR, Li Q, Wan T, He B, Han J, Chen HX, Yang FX, Wang W, Xu HZ, Ye T, Zha BB. Galactosylated chitosan/5-fluorouracil nanoparticles inhibit mouse hepatic cancer growth and its side effects. World J Gastroenterol 2012; 18: 6076-6087 [PMID: 23155336 DOI: 10.3748/wjg.v18.i42.6076]
76. Wang Q, Zhang L, Hu W, Hu ZH, Bei YY, Xu JY, Wang WJ, Zhang XN, Zhang Q. Norcantharidin-associated galactosylated chitosan nanoparticles for hepatocyte-targeted delivery. Nanomedicine 2010; 6: 371-381 [PMID: 19699319 DOI: 10.1016/j.nano.2009.07.006]
77. Liu D, Hu H, Zhang J, Zhao X, Tang X, Chen D. Drug pHsensitive release in vitro and targeting ability of polyamidoamine dendrimer complexes for tumor cells. Chem Pharm Bull (Tokyo) 2011; 59: 63-71 [PMID: 21212549]
78. Kamimoto Y, Tanabe D, Tashiro S, Hiraoka T, Miyauchi Y. Changes in receptor-mediated endocytosis in liver sinusoidal cells after partial hepatectomy in the rat. Liver 1994; 14: 141-147 [PMID: 7521505]
79. Roseng L, Tolleshaug H, Berg T. Uptake, intracellular transport, and degradation of polyethylene glycol-modified asialofetuin in hepatocytes. J Biol Chem 1992; 267: 22987-22993 [PMID: 1385410]
80. Becker S, Spiess M, Klenk HD. The asialoglycoprotein receptor is a potential liver-specific receptor for Marburg virus. J Gen Virol 1995; 76 (Pt 2): 393-399 [PMID: 7844558]
81. Chang AG, Wu GY. Gene therapy: applications to the treatment of gastrointestinal and liver diseases. Gastroenterology 1994; 106: 1076-1084 [PMID: 8143976]
82. Hara T, Kuwasawa H, Aramaki Y, Takada S, Koike K, Ishidate K, Kato H, Tsuchiya S. Effects of fusogenic and DNA-binding amphiphilic compounds on the receptor-mediated gene transfer into hepatic cells by asialofetuin-labeled liposomes. Biochim Biophys Acta 1996; 1278: 51-58 [PMID: 8611607]
83. Ishihara H, Hayashi Y, Hara T, Aramaki Y, Tsuchiya S, Koike K. Specific uptake of asialofetuin-tacked liposomes encapsulating interferon-gamma by human hepatoma cells and its inhibitory effect on hepatitis B virus replication. Biochem Biophys Res Commun 1991; 174: 839-845 [PMID: 1704230]
84. Motoyama K, Nakashima Y, Aramaki Y, Hirayama F, Uekama K, Arima H. In Vitro Gene Delivery Mediated by Asialofetuin-Appended Cationic Liposomes Associated with γ-Cyclodextrin into Hepatocytes. J Drug Deliv 2011; 2011: 476137 [PMID: 21490752 DOI: 10.1155/2011/476137]
85. Nasr M, Nafee N, Saad H, Kazem A. Improved antitumor activity and reduced cardiotoxicity of epirubicin using hepatocyte-targeted nanoparticles combined with tocotrienols against hepatocellular carcinoma in mice. Eur J Pharm Biopharm 2014; 88: 216-225 [PMID: 24813390 DOI: 10.1016/j.ejpb.2014.04.016]
86. Han L, Tang C, Yin C. Oral delivery of shRNA and siRNA via multifunctional polymeric nanoparticles for synergistic cancer therapy. Biomaterials 2014; 35: 4589-4600 [PMID: 24613049 DOI: 10.1016/j.biomaterials.2014.02.027]
87. Sohda T, Iwata K, Kitamura Y, Suzuki N, Takeyama Y, Irie M, Anan A, Nakane H, Yoshikane M, Watanabe H, Sakisaka S. Reduced expression of low-density lipoprotein receptor in hepatocellular carcinoma with paraneoplastic hypercholesterolemia. J Gastroenterol Hepatol 2008; 23: e153-e156 [PMID: 17784865 DOI: 10.1111/j.1440-1746.2007.05115.x]
88. Chang JE, Yoon IS, Sun PL, Yi E, Jheon S, Shim CK. Anticancer efficacy of photodynamic therapy with hematoporphyrin-modified, doxorubicin-loaded nanoparticles in liver cancer. J Photochem Photobiol B 2014; 140: 49-56 [PMID: 25090224 DOI: 10.1016/j.jphotobiol.2014.07.005]
89. Ding Y, Wang W, Feng M, Wang Y, Zhou J, Ding X, Zhou X, Liu C, Wang R, Zhang Q. A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy. Biomaterials 2012; 33: 8893-8905 [PMID: 22979990 DOI: 10.1016/j.biomaterials.2012.08.057]
90. Varshosaz J, Jafarian A, Salehi G, Zolfaghari B. Comparing different sterol containing solid lipid nanoparticles for targeted delivery of quercetin in hepatocellular carcinoma. J Liposome Res 2014; 24: 191-203 [PMID: 24354715 DOI: 10.3109/08982104.201 3.868476]
91. Siebert HC, Born K, André S, Frank M, Kaltner H, von der Lieth CW, Heck AJ, Jiménez-Barbero J, Kopitz J, Gabius HJ. Carbohydrate chain of ganglioside GM1 as a ligand: identification of the binding strategies of three 15 mer peptides and their divergence from the binding modes of growth-regulatory galectin-1 and cholera toxin. Chemistry 2005; 12: 388-402 [PMID: 16267866 DOI: 10.1002/chem.200500505]
92. Zhao L, Su R, Cui W, Shi Y, Liu L, Su C. Preparation of biocompatible heat-labile enterotoxin subunit B-bovine serum albumin nanoparticles for improving tumor-targeted drug delivery via heat-labile enterotoxin subunit B mediation. Int J Nanomedicine 2014; 9: 2149-2156 [PMID: 24851048 DOI: 10.2147/IJN.S60764]
93. Bull JM, Scott GL, Strebel FR, Nagle VL, Oliver D, Redwine M, Rowe RW, Ahn CW, Koch SM. Fever-range whole-body thermal therapy combined with cisplatin, gemcitabine, and daily interferonalpha: a description of a phase I-II protocol. Int J Hyperthermia 2008; 24: 649-662 [PMID: 18608594 DOI: 10.1080/02656730802 104740]
94. Raoof M, Corr SJ, Zhu C, Cisneros BT, Kaluarachchi WD, Phounsavath S, Wilson LJ, Curley SA. Gold nanoparticles and radiofrequency in experimental models for hepatocellular carcinoma. Nanomedicine 2014; 10: 1121-1130 [PMID: 24650884 DOI: 10.1016/j.nano.2014.03.004]
95. Chen J, Zhu S, Tong L, Li J, Chen F, Han Y, Zhao M, Xiong W. Superparamagnetic iron oxide nanoparticles mediated (131)I-hVEGF siRNA inhibits hepatocellular carcinoma tumor growth in nude mice. BMC Cancer 2014; 14: 114 [PMID: 24555445 DOI: 10.1186/1471-2407-14-114]
96. Ma X, Cheng Z, Jin Y, Liang X, Yang X, Dai Z, Tian J. SM5-1-conjugated PLA nanoparticles loaded with 5-fluorouracil for targeted hepatocellular carcinoma imaging and therapy. Biomaterials 2014; 35: 2878-2889 [PMID: 24411331 DOI: 10.1016/j.biomaterials.2013. 12.045]
97. Wang L, Su W, Liu Z, Zhou M, Chen S, Chen Y, Lu D, Liu Y, Fan Y, Zheng Y, Han Z, Kong D, Wu JC, Xiang R, Li Z. CD44 antibodytargeted liposomal nanoparticles for molecular imaging and therapy of hepatocellular carcinoma. Biomaterials 2012; 33: 5107-5114 [PMID: 22494888 DOI: 10.1016/j.biomaterials.2012.03.067]
98. De Luca LM. Retinoids and their receptors in differentiation, embryogenesis, and neoplasia. FASEB J 1991; 5: 2924-2933 [PMID: 1661245]
99. Sever CE, Locker J. Expression of retinoic acid alpha and beta receptor genes in liver and hepatocellular carcinoma. Mol Carcinog 1991; 4: 138-144 [PMID: 1710463]
100. Schug TT, Berry DC, Shaw NS, Travis SN, Noy N. Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors. Cell 2007; 129: 723-733 [PMID: 17512406 DOI: 10.1016/j.cell.2007.02.050]
101. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001; 1: 181-193 [PMID: 11902573 DOI: 10.1038/35106036]
102. Recchia F, Saggio G, Cesta A, Candeloro G, Di Blasio A, Amiconi G, Lombardo M, Nuzzo A, Lalli A, Alesse E, Necozione S, Rea S. Phase II study of interleukin-2 and 13-cis-retinoic acid as maintenance therapy in metastatic colorectal cancer. Cancer Immunol Immunother 2007; 56: 699-708 [PMID: 16955297 DOI: 10.1007/s00262-006-0224-9]
103. Singh B, Murphy RF, Ding XZ, Roginsky AB, Bell RH, Adrian TE. On the role of transforming growth factor-beta in the growth inhibitory effects of retinoic acid in human pancreatic cancer cells. Mol Cancer 2007; 6: 82 [PMID: 18157915 DOI: 10.1186/1476-4598-6-82]
104. Tsimberidou AM, Tirado-Gomez M, Andreeff M, O'Brien S, Kantarjian H, Keating M, Lopez-Berestein G, Estey E. Singleagent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series. Leuk Lymphoma 2006; 47: 1062-1068 [PMID: 16840198 DOI: 10.1080/10428190500463932]
105. Varshosaz J, Hassanzadeh F, Sadeghi H, Ghelich Khan Z, Rostami M. Retinoic Acid Decorated Albumin-Chitosan Nanoparticles for Targeted Delivery of Doxorubicin Hydrochloride in Hepatocellular Carcinoma. J Nanomaterials 2013; 2013: 12 [DOI: 10.1155/2013/254127]
106. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110: 673-687 [PMID: 12297042]
107. Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 1996; 12: 697-715 [PMID: 8970741 DOI: 10.1146/annurev.cellbio.12.1.697]
108. Mei L, Fu L, Shi K, Zhang Q, Liu Y, Tang J, Gao H, Zhang Z, He Q. Increased tumor targeted delivery using a multistage liposome system functionalized with RGD, TAT and cleavable PEG. Int J Pharm 2014; 468: 26-38 [PMID: 24709209 DOI: 10.1016/j.ijpharm.2014.04.008]
109. Torchilin VP. Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv Drug Deliv Rev 2008; 60: 548-558 [PMID: 18053612 DOI: 10.1016/j.addr.2007.10.008]
110. Duchardt F, Fotin-Mleczek M, Schwarz H, Fischer R, Brock R. A comprehensive model for the cellular uptake of cationic cellpenetrating peptides. Traffic 2007; 8: 848-866 [PMID: 17587406 DOI: 10.1111/j.1600-0854.2007.00572.x]
111. Pappalardo JS, Quattrocchi V, Langellotti C, Di Giacomo S, Gnazzo V, Olivera V, Calamante G, Zamorano PI, Levchenko TS, Torchilin VP. Improved transfection of spleen-derived antigenpresenting cells in culture using TATp-liposomes. J Control Release 2009; 134: 41-46 [PMID: 19059290 DOI: 10.1016/j.jconrel.2008.11.006]
112. Cai LL, Liu P, Li X, Huang X, Ye YQ, Chen FY, Yuan H, Hu FQ, Du YZ. RGD peptide-mediated chitosan-based polymeric micelles targeting delivery for integrin-overexpressing tumor cells. Int J Nanomedicine 2011; 6: 3499-3508 [PMID: 22282676 DOI: 10.2147/IJN.S26670]
113. Pilapong C, Sitthichai S, Thongtem S, Thongtem T. Smart magnetic nanoparticle-aptamer probe for targeted imaging and treatment of hepatocellular carcinoma. Int J Pharm 2014; 473: 469-474 [PMID: 25089503 DOI: 10.1016/j.ijpharm.2014.07.036]
114. Wu C, Gong F, Pang P, Shen M, Zhu K, Cheng D, Liu Z, Shan H. An RGD-modified MRI-visible polymeric vector for targeted siRNA delivery to hepatocellular carcinoma in nude mice. PLoS One 2013; 8: e66416 [PMID: 23922634 DOI: 10.1371/journal. pone.0066416]
115. Loyer P, Bedhouche W, Huang ZW, Cammas-Marion S. Degradable and biocompatible nanoparticles decorated with cyclic RGD peptide for efficient drug delivery to hepatoma cells in vitro. Int J Pharm 2013; 454: 727-737 [PMID: 23747504 DOI: 10.1016/j.ijpharm.2013.05.060]
116. Bogorad RL, Yin H, Zeigerer A, Nonaka H, Ruda VM, Zerial M, Anderson DG, Koteliansky V. Nanoparticle-formulated siRNA targeting integrins inhibits hepatocellular carcinoma progression in mice. Nat Commun 2014; 5: 3869 [PMID: 24844798 DOI: 10.1038/ncomms4869]
117. Agarwal A, Saraf S, Asthana A, Gupta U, Gajbhiye V, Jain NK. Ligand based dendritic systems for tumor targeting. Int J Pharm 2008; 350: 3-13 [PMID: 18162345 DOI: 10.1016/j.ijpharm.2007.09.024]
118. Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 2009; 9: 167-181 [PMID: 19238149 DOI: 10.1038/nrc2583]
119. Elwood PC. Molecular cloning and characterization of the human folate-binding protein cDNA from placenta and malignant tissue culture (KB) cells. J Biol Chem 1989; 264: 14893-14901 [PMID: 2768245]
120. Lacey SW, Sanders JM, Rothberg KG, Anderson RG, Kamen BA. Complementary DNA for the folate binding protein correctly predicts anchoring to the membrane by glycosyl-phosphatidylinositol. J Clin Invest 1989; 84: 715-720 [PMID: 2527252 DOI: 10.1172/JCI114220]
121. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 2005; 338: 284-293 [PMID: 15745749 DOI: 10.1016/j.ab.2004.12.026]
122. Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 1994; 73: 2432-2443 [PMID: 7513252]
123. Wu M, Gunning W, Ratnam M. Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Cancer Epidemiol Biomarkers Prev 1999; 8: 775-782 [PMID: 10498396]
124. Leamon CP. Folate-targeted drug strategies for the treatment of cancer. Curr Opin Investig Drugs 2008; 9: 1277-1286 [PMID: 19037834]
125. Varshosaz J, Hassanzadeh F, Sadeghi Aliabadi H, Nayebsadrian M, Banitalebi M, Rostami M. Synthesis and characterization of folatetargeted dextran/retinoic acid micelles for doxorubicin delivery in acute leukemia. Biomed Res Int 2014; 2014: 525684 [PMID: 24719872 DOI: 10.1155/2014/525684]
126. Varshosaz J, Taymouri S, Hassanzadeh F, Javanmard SH, Rostami M. Folated synperonic-cholesteryl hemisuccinate polymeric micelles for the targeted delivery of docetaxel in melanoma. Biomed Res Int 2015; 2015: 746093 [PMID: 25839040 DOI: 10.1155/2015/746093]
127. Yang T, Li B, Qi S, Liu Y, Gai Y, Ye P, Yang G, Zhang W, Zhang P, He X, Li W, Zhang Z, Xiang G, Xu C. Co-delivery of doxorubicin and Bmi1 siRNA by folate receptor targeted liposomes exhibits enhanced anti-tumor effects in vitro and in vivo. Theranostics 2014; 4: 1096-1111 [PMID: 25285163 DOI: 10.7150/thno.9423]
128. Zhang L, Gong F, Zhang F, Ma J, Zhang P, Shen J. Targeted therapy for human hepatic carcinoma cells using folatefunctionalized polymeric micelles loaded with superparamagnetic iron oxide and sorafenib in vitro. Int J Nanomedicine 2013; 8: 1517-1524 [PMID: 23620667 DOI: 10.2147/IJN.S43263]
129. Cao N, Cheng D, Zou S, Ai H, Gao J, Shuai X. The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells. Biomaterials 2011; 32: 2222-2232 [PMID: 21186059 DOI: 10.1016/j.biomaterials.201 0.11.061]
130. Li X, Li H, Yi W, Chen J, Liang B. Acid-triggered core crosslinked nanomicelles for targeted drug delivery and magnetic resonance imaging in liver cancer cells. Int J Nanomedicine 2013; 8: 3019-3031 [PMID: 23976852 DOI: 10.2147/IJN.S45767]
131. Xu Z, Zhang Z, Chen Y, Chen L, Lin L, Li Y. The characteristics and performance of a multifunctional nanoassembly system for the co-delivery of docetaxel and iSur-pDNA in a mouse hepatocellular carcinoma model. Biomaterials 2010; 31: 916-922 [PMID: 19846217 DOI: 10.1016/j.biomaterials.2009.09.103]
132. Maeng JH, Lee DH, Jung KH, Bae YH, Park IS, Jeong S, Jeon YS, Shim CK, Kim W, Kim J, Lee J, Lee YM, Kim JH, Kim WH, Hong SS. Multifunctional doxorubicin loaded superparamagnetic iron oxide nanoparticles for chemotherapy and magnetic resonance imaging in liver cancer. Biomaterials 2010; 31: 4995-5006 [PMID: 20347138 DOI: 10.1016/j.biomaterials.2010.02.068]
133. Viota JL, Carazo A, Munoz-Gamez JA, Rudzka K, Gómez-Sotomayor R, Ruiz-Extremera A, Salmerón J, Delgado AV. Functionalized magnetic nanoparticles as vehicles for the delivery of the antitumor drug gemcitabine to tumor cells. Physicochemical in vitro evaluation. Mater Sci Eng C Mater Biol Appl 2013; 33: 1183-1192 [PMID: 23827558 DOI: 10.1016/j.msec.2012.12.009]
134. Fan L, Li F, Zhang H, Wang Y, Cheng C, Li X, Gu CH, Yang Q, Wu H, Zhang S. Co-delivery of PDTC and doxorubicin by multifunctional micellar nanoparticles to achieve active targeted drug delivery and overcome multidrug resistance. Biomaterials 2010; 31: 5634-5642 [PMID: 20430433 DOI: 10.1016/j.biomateria ls.2010.03.066]
135. Jin H, Yang P, Cai J, Wang J, Liu M. Photothermal effects of folate-conjugated Au nanorods on HepG2 cells. Appl Microbiol Biotechnol 2012; 94: 1199-1208 [PMID: 22406860 DOI: 10.1007/s00253-012-3935-1]
136. Wang L, Li M, Zhang N. Folate-targeted docetaxel-lipid-based-nanosuspensions for active-targeted cancer therapy. Int J Nanomedicine 2012; 7: 3281-3294 [PMID: 22802688 DOI: 10.2147/IJN.S32520]
137. Li JC, Sha XY, Zhang LJ, Fang XL. [9-nitrocamptothecin nanostructured lipid carrier system: in vitro releasing characteristics, uptake by cells, and tissue distribution in vivo]. Yao Xue Xue Bao 2005; 40: 970-975 [PMID: 16499078]
138. Krishna AD, Mandraju RK, Kishore G, Kondapi AK. An efficient targeted drug delivery through apotransferrin loaded nanoparticles. PLoS One 2009; 4: e7240 [PMID: 19806207 DOI: 10.1371/journal.pone.0007240]
139. Golla K, Cherukuvada B, Ahmed F, Kondapi AK. Efficacy, safety and anticancer activity of protein nanoparticle-based delivery of doxorubicin through intravenous administration in rats. PLoS One 2012; 7: e51960 [PMID: 23284832 DOI: 10.1371/journal. pone.0051960]
140. Luo LZ, Jin HW, Huang HQ. Transferrin-cisplatin specifically deliver cisplatin to HepG2 cells in vitro and enhance cisplatin cytotoxicity. J Proteomics 2012; 77: 237-250 [PMID: 22986151 DOI: 10.1016/j.jprot.2012.08.023]
141. Malarvizhi GL, Retnakumari AP, Nair S, Koyakutty M. Transferrin targeted core-shell nanomedicine for combinatorial delivery of doxorubicin and sorafenib against hepatocellular carcinoma. Nanomedicine 2014; 10: 1649-1659 [PMID: 24905399 DOI: 10.1016/j.nano.2014.05.011]
142. Ashley CE, Carnes EC, Phillips GK, Durfee PN, Buley MD, Lino CA, Padilla DP, Phillips B, Carter MB, Willman CL, Brinker CJ, Caldeira Jdo C, Chackerian B, Wharton W, Peabody DS. Cellspecific delivery of diverse cargos by bacteriophage MS2 virus-like particles. ACS Nano 2011; 5: 5729-5745 [PMID: 21615170 DOI: 10.1021/nn201397z]